Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Sagent Pharmaceuticals (SGNT) Stock Price

Media headlines about Sagent Pharmaceuticals (NASDAQ:SGNT) have been trending somewhat positive on Friday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sagent Pharmaceuticals earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.855607991777 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/11/03/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-sagent-pharmaceuticals-sgnt-stock-price.html.

Sagent Pharmaceuticals Company Profile

Sagent Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market.

Insider Buying and Selling by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)

What are top analysts saying about Sagent Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sagent Pharmaceuticals Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit